TELA Bio, Inc. TELA
Nov 4, 2026, 1:06 PM EST
- YTD
- -33.88%
- 1 year
- -39.52%
- Market cap
- 35.22M
- Revenue (ttm)
- 68.65M
- Profit margin
- -60.49%
- EPS (ttm)
- -0.77
- Shares out
- 39.39M
- Forward P/E
- -4.31
- YTD return
- -33.88%
- 1-year return
- -39.52%
- Volume
- 38.63K
- Avg volume
- 223.55K
- Open
- 0.82
- Previous close
- 0.802
- Day's range
- 0.7801 – 0.8526
- 52-week range
- 0.501 – 1.50
- Beta
- 0.97
- Analysts
- Strong Buy
- Price target
- 9.20 (+1079.2%)
- Earnings date
- Aug 12, 2024
1D +0.0080 (+1.00%)
Key statistics
- Enterprise value
- 95.57M
- PEG ratio
- 0.00
- Price / sales
- 1.68
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 25.90%
- Free cash flow
- 0
- Total cash
- 17.30M
- Total debt
- 42.43M
- Return on equity
- -342.04%
- Short % of float
- 0.98%
- 50-day average
- 2.85
- 200-day average
- 4.02
Analyst view
Consensus: strong buy
- Target (low)
- 5.00
- Target (mean)
- 9.20
- Target (high)
- 12.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.222.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.37 | -0.42 | -0.05 | -13.51% |
| Aug 12, 2024 | Jun 1, 2024 | -0.45 | -0.51 | -0.06 | -13.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.48 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.48 | -0.23 | +0.25 | +52.08% |
| Mar 21, 2024 | Dec 1, 2023 | -0.44 | -0.53 | -0.09 | -20.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Piper Sandler | main | Overweight | Overweight |
| Oct 4, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 13, 2024 | Lake Street | main | Buy | Buy |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 13, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Aug 13, 2024 | Piper Sandler | main | Overweight | Overweight |
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- telabio.com
News
TELA Bio to Announce Third Quarter 2026 Financial Results 
TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript 
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement 
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts 
Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2 
Insider Buying: TELA Bio (NASDAQ:TELA) Director Acquires $30,500.00 in Stock 
TELA Bio (NASDAQ:TELA) versus Baxter International (NYSE:BAX) Head to Head Analysis 
TELA Bio Announces $17M Annual Expense Reduction Through 20% Workforce Streamlining and Resource Optimization, Extending Cash Runway Into 2028 
TELA Bio COO And CFO Roberto Cuca To Step Down Effective Immediately 
TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative
Your note
Sign in to keep a note on TELA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZARBARZIN KURT | Director | Stock Award(Grant) | Jun 3, 2024 | 10,520 |
| BURGESS VINCENT J | Director | Stock Award(Grant) | Jun 3, 2024 | 15,380 |
| COLLERAN LISA N | Director | Stock Award(Grant) | Jun 3, 2024 | 10,520 |
| CUCA ROBERTO | Chief Operating Officer | Purchase | Oct 23, 2024 | 155,388 |
| EVANS DOUGLAS G | Director | Stock Award(Grant) | Jun 3, 2024 | 10,520 |
| FIRESTONE GREGORY A | Officer | Purchase | Oct 23, 2024 | 57,279 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Woodlands Management Inc. | 10.44% | 4,110,709 | 12.04M | Sep 29, 2024 |
| AIGH Capital Management LLC | 6.27% | 2,469,373 | 7.24M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 5.49% | 2,161,185 | 6.33M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 4.86% | 1,915,126 | 5.61M | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 2.86% | 1,124,928 | 3.30M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.82% | 1,110,000 | 3.25M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.63% | 643,290 | 1.88M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.58% | 226,799 | 664.52K | Sep 29, 2024 |
| Federated Hermes Kaufmann Fund | 0.39% | 153,969 | 451.13K | Jul 30, 2024 |
| Jacob Discovery Fd | 0.35% | 139,775 | 409.54K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.26% | 101,000 | 295.93K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 81,201 | 237.92K | Oct 30, 2024 |